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Abstract
Background: The zinc finger protein Znf202 is a transcriptional suppressor of lipid related genes and has been linked to
hypoalphalipoproteinemia. A functional role of Znf202 in lipid metabolism in vivo still remains to be established.
Methodology and Principal Findings: We generated mouse Znf202 expression vectors, the functionality of which was
established in several in vitro systems. Next, effects of adenoviral znf202 overexpression in vivo were determined in normo-
as well as hyperlipidemic mouse models. Znf202 overexpression in mouse hepatoma cells mhAT3F2 resulted in
downregulation of members of the Apoe/c1/c2 and Apoa1/c3/a4 gene cluster. The repressive activity of Znf202 was firmly
confirmed in an apoE reporter assay and Znf202 responsive elements within the ApoE promoter were identified. Adenoviral
Znf202 transfer to Ldlr2/2 mice resulted in downregulation of apoe, apoc1, apoa1, and apoc3 within 24 h after gene
transfer. Interestingly, key genes in bile flux (abcg5/8 and bsep) and in bile acid synthesis (cyp7a1) were also downregulated.
At 5 days post-infection, the expression of the aforementioned genes was normalized, but mice had developed severe
hepatosteatosis accompanied by hypercholesterolemia and hypoalphalipoproteinemia. A much milder phenotype was
observed in wildtype mice after 5 days of hepatic Znf202 overexpression. Interestingly and similar to Ldl2/2 mice, HDL-
cholesterol levels in wildtype mice were lowered after hepatic Znf202 overexpression.
Conclusion/Significance: Znf202 overexpression in vivo reveals an important role of this transcriptional regulator in liver
lipid homeostasis, while firmly establishing the proposed key role in the control of HDL levels.
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Introduction
Hypoalphalipoproteinemia is characterized by subnormal levels
of serum high density lipoprotein (HDL) irrespective of other
lipoprotein or lipid levels. It is a common lipoprotein abnormality
in patients with coronary heart disease and low HDL levels were
shown in various studies to be linked to risk factors like diabetes
and hyperlipidemia [1,2]. By acting as a lipid acceptor in the
reverse cholesterol transport and by its anti-inflammatory prop-
erties, HDL is considered to be atheroprotective [3–5]. However,
a causal link between genetically decreased HDL levels and an
increased risk in coronary heart disease has not been established
yet and the therapeutic potential of HDL is still to be determined
[6–10].
The zinc finger protein 202 (Znf202) gene has been identified in
the chromosomal region 11q23 that is linked to heritable
hypoalphalipoproteinemia in Utah pedigrees and distinct from
an apolipoprotein gene cluster ApoAI/CIII/AIV/AV [11,12]. In
contrast, a recent publication failed to confirm a correlation
between genetic variations in Znf202 and HDL levels [13].
However, a sequence variation in the promoter of Znf202 did
predict atherosclerosis and Ischemic Heart Disease [14]. Znf202 is
a Cys2-His2 zinc-finger protein family member containing a
leucine-rich SCAN domain and a Krueppel-associated box
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(KRAB) [15,16]. Although the specific function of these domains is
still under investigation, the presence of a KRAB domain in
Znf202 is suggestive of transcriptional repressor activity [17]. This
is corroborated by in vitro findings showing repressional activity of
Znf202 on a range of target genes involved in lipid metabolism
including ATP-binding cassette (ABC) transporters Abca1, Abcg1
and apolipoproteins Apoe and Apoa4, in hepatoma cells [12] as well
as monocytes [18]. It was shown that Znf202 interacts with GnT
response motifs in the respective promoter regions of these genes.
Despite the detailed insights in vitro, very little is known of Znf202
mediated gene regulation in vivo. Moreover, the contribution of
Znf202 to the regulation of serum lipids and lipoprotein
metabolism is up till now unclear. But even with the contrasting
findings in epidemiology studies, its activity pattern in vitro fuels
the notion that Znf202 plays an important role in lipid homeostasis
and is a potential candidate for a targeted therapy in cardiovas-
cular diseases.
Considering the repressive nature of the transcription factor
and, more specifically, its negative effect on the expression levels of
HDL-related genes, the observed heritable low HDL cholesterol
levels in those aforementioned Utah families are most likely the
result of elevated activity of Znf202. Hence, we have investigated
ZNF202 overexpression in vivo in both normo- (C57Bl/6J) as well
as in hyperlipidemic (low density lipoprotein receptor knockout;
Ldlr2/2) mice. To this end, we have generated an adenovirus
vector carrying the mouse Znf202 gene. After in vitro analysis for
its repressive activity, we assessed effects of hepatic Znf202
overexpression on serum lipid and lipoprotein levels as well as
on the hepatic gene expression profile. Along with the suppressive
effect on HDL cholesterol levels observed upon Znf202 overex-
pression in mice, these data clearly demonstrate that the
transcription factor Znf202 can act as a key regulator in lipid
metabolism.
Materials and Methods
Cell Culture
Mouse hepatoma mhAT3F2 cells [19] were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) with F-12 (Gibco)
supplemented with 10% fetal calf serum (Gibco), 100 IU/ml
Penicillin, 100 mg/ml Streptomycin, 20 mM GlutaMAX I,
400 nM Insulin (Sigma), 10 nM Dexamethasone (Sigma). Per.C6
and 911 cells [20,21] were both cultured in DMEM (Gibco),
supplemented with 10% fetal calf serum (Gibco), 100 IU/ml
Penicillin, 100 mg/ml Streptomycin, 2 mM GlutaMAX I (Gibco),
at which medium for Per.C6 cells was also supplemented with
10 mM MgCl2. For large scale production of recombinant
adenovirus in Per.C6 cells the 10% fetal calf serum was substituted
with 2% horse serum (Gibco).
Construction of Expression and Reporter Gene
Constructs
Mouse Znf202 was obtained from liver cDNA of C57Bl/6JIco
by PCR (nucleotide positions 186 to 2208, GenBank accession
number AF292648), with forward primer 59 -GGTACCATAA-
CACCCAAGAGCCAGGA -39 containing a KpnI site and a
reverse primer 59 -TCTAGACAGAACCCATCCGTCTCAGT -
39 containing a XbaI site. The amplicon Znf202 was cloned into
pShuttleCMV and pAdTrackCMV via these restriction sites [22].
The ApoE promoter (GenBank accession number D00466) was
cloned from cosmid mAPOE/B1 cos27 (C2RB) by PCR. Four
different promoter constructs were generated based on the absence
or presence of GnT motifs, and forward primers were chosen
accordingly and elongated at the 59 with a Kpn1 restriction site to
facilitate cloning. The promoter sequences were amplified by PCR
with a common exon-1 targeted reverse primer carrying a 59
Hind3 site (table S1) and amplicons cloned into the pCR.2.1
TOPO vector of the TOPO TA Cloning kit (Invitrogen).
Subsequently, KpnI-HindIII fragments were cut out of the
pCR.2.1 vector and inserted into KpnI-HindIII restricted pGL3-
Basic (Promega). All sequences were verified by sequencing
(LGTC, Leiden).
Luciferase Reporter Assays
Transient transfections in mhAT3F2 cells were performed in 6-
well plates using Fugene 6 (Roche Molecular Biochemicals).
Luciferase activity of 200 ng transfected promoter-reporter
constructs, with promoterless pGL3-basic serving as control, was
measured by co-transfecting the cells with 100 ng of pCMV-LacZ.
After 24 h, the cells were lysed with reporter lysis buffer (Promega)
and luciferase activity was determined according manufacturer’s
protocol (Promega) in a monolight luminometer (BD Biosciences).
b-galactosidase was measured using the b-Galactosidase Enzyme
Assay System in reporter lysis buffer (Promega). The effect of
Znf202 overexpression on transcription regulation of the reporter
gene constructs was determined by co-transfecting mhAT3F2 cells
with 100 ng of a reporter gene construct and 1900 ng of the
expression vector pShuttleCMV-Znf202 or an empty pShut-
tleCMV control vector. Luciferase activities were measured as
described above and normalized for protein concentrations using
BCA System (Pierce).
Whole Cell Extract Preparation and Electrophoretic
Mobility Shift Assays
911 cells were transfected with 5 mg pAdTrackCMV-Znf202 or
control plasmid on 10 cm dishes using LipofectAMINE plus kit.
After 40 hours cells were harvested, whole cell extract were
obtained, and protein concentrations were determined by a
Bradford assay (BioRad). Double-stranded [c-32P]-labeled DNA
probes containing the Znf202 binding sites, the consensus GnT
oligonucleotide, the putative 2564 and 2678 Znf202 binding
oligonucleotides, as well as a control unrelated fragment contain-
ing the pleiohomeotic (PHO) consensus binding site were
prepared. The DNA-binding activity of mouse Znf202 in whole
cell extracts to these probes was studied by means of electropho-
retic mobility shift assay (EMSA). A detailed description of the
EMSA protocol is provided in the Supplementary Materials and
Methods (Text S1).
Generation of Adenoviral Constructs
Recombinant adenoviral plasmids by homologous recombina-
tion of pShuttleCMV-Znf202 with pAdEasy1 were generated in
BJ5183 cells (Stratagene) as described by He et al. [22].
Ad.Znf202 was produced in Per.C6 cells (Crucell) and after
purification via CsCl centrifugation, the yield was assessed via a
plaque assay in 911 cells. A detailed description of these techniques
is provided in supplementary Materials and Methods (Text S1).
The construction of control virus Ad.mock (Ad-LacZ) has been
described previously [23].
Animals
All animal work was approved by the Ethics Committee for
Animal Experiments of the Leiden University (approval ID:
ADEC 03054) and the experimental protocols complied with the
national guidelines for use of experimental animals. Male C57Bl/
6JIco and Ldlr2/2 mice on a C57Bl/6JIco genetic background
were given a standard mouse diet Chow (Hope Farms, Nether-
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Figure 1. Znf202 overexpression leads to repression of members of the apoe/c1/c2 and apoa1/c3/a4/a5 gene clusters in mhAT3F2
and inhibits mouse apoE promoter activity. (A) MhAT3F2 cells were transduced with Ad.Znf202 (black bars) or Ad.LacZ (grey bars)(MOI = 100)
and mRNA levels were measured via quantitative real time PCR at 24 hours post-infection. Data represent average of four transductions for each
group (mean 6 S.D) and expressions are relative to HPRT. (B) MhAT3F2 cells were transfected with mouse apoE promotor-reporter constructs,
carrying a 729 bp fragment of the mouse apoE promoter lacking the downstream intron-1 (2705 to +24) or truncated variants thereof. Co-
transfection with pCMV-LacZ served as a control for transfection efficiency. Luciferase activity was normalized for b-galactosidase activity (n = 4, mean
6 S.D.). (C) MhAT3F2 cells were transiently cotransfected with the indicated reporter constructs and Znf202 expression vector (black bars). As control
expression vector pShuttleCMV-empty was used (grey bars). After 24 hours cells were harvested and luciferase activities (n = 4, mean 6 S.D.)
measured and normalized for protein concentration.
doi:10.1371/journal.pone.0057492.g001
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lands) and housed in conventional cages with free access to water
and food.
Treatment with Recombinant Adenovirus
In vitro – Murine hAT3F2 hepatoma cells were seeded in a 12-
wells plate and grown to 70% confluency. Cells were infected with
either Ad.Znf202 or control Ad-mock (MOI= 100). After 24 hours
the cells were harvested and total RNA was isolated. In vivo -
Recombinant adenovirus, 26109 pfu in 200 ml of PBS, was
administered by injection into the tail vein of mice at the age of
28–32 weeks. Blood samples were taken via tail bleeding as
indicated in the legends. After 24 hrs or 5 days post-infection, mice
were sacrificed, liver sections were removed, snap-frozen in liquid
nitrogen and stored at 280uC. Liver cryosections were stained
with Oil Red-O (Sigma Diagnostics) and hematoxylin (Sigma
Diagnostics).
Determination of mRNA Levels
Total RNA was isolated from treated AT3F2 and liver samples
using Trizol according to the manufacturer’s protocol (Invitrogen).
Purified RNA was treated with RQ1 RNase-free DNase
(Promega, 1 units/2 mg of total RNA) and reverse transcribed
with SuperScript II Reverse Transcriptase (Invitrogen) according
to the protocols supplied by the manufacturers. Quantitative gene
expression analysis was performed on an ABI prism7700 Sequence
Detection System using SYBR green (Applied Biosystems). PCR
primers (table S2) were designed on the basis of Primer Express
software with the manufacturer’s default settings (Applied Biosys-
tems) and validated for identical efficiencies. Cyclophilin, hypo-
xanthine-guanine phosphoribosyl transferase (HPRT) and acidic
ribosomal phosphoprotein P0 (36B4) were used as control genes.
Lipid and Lipoprotein Analysis
Blood was collected from each individual mouse before (day 0;
baseline samples) and at day 1 or at day 4 and 5 after adenovirus
injection through tail bleeding in diethyl-p-nitro phenyl phosphate
(paraoxon) coated capillary tubes, after a 4-hour fasting period
[24]. Total plasma cholesterol (Boehringer-Mannheim) and
triglycerides (Sigma Chemical Co) were measured enzymatically.
From pooled plasma samples per treatment group, obtained at day
4, lipoprotein distribution was determined by fast performance
liquid chromatography (FPLC). A volume of 70 ml was injected
onto a Superose6 column (3.2630 mm, AKTA-system, Pharma-
cia). Elution fractions of 50 ml were collected and assayed for
cholesterol and triglyceride levels as described above. For
measurement of liver lipids, frozen (N2) liver samples were
Figure 2. The Znf202 specifically binds to the alleged response elements 2678 and 2564 within the 2705/2362 region of the
mouse apoE promoter. (A) DNA fragments used in this study containing the putative Znf202 binding sequence. The putative consensus
sequences are underlined. (B) EMSA with labeled DNA fragments GnT (lanes 1–10), 2678 (lanes 11–20), 2564 (lanes 21–30), and PHO (lanes 31–35)
described above. Reactions contained the indicated amount (0.1–0.6 mg) of whole cell extract made from either control 911 cells, or from 911 cells
overexpressing Znf202. Competition experiments using 50-fold excess of unlabeled GnT oligonucleotide (lanes 4,7 and 10), 2678 oligonucleotide
(lanes 14,17 and 20), or -564 oligonucleotide (lanes 24,27 and 30) confirmed the specificity of Znf202 binding to both GnT elements. Arrowheads
indicate the mobility of unbound DNA and Znf202 protein bound DNA.
doi:10.1371/journal.pone.0057492.g002
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Figure 3. Hepatic Znf202 overexpression reduces HDL-cholesterol in Ldlr2/2 and WT mice. Blood samples were drawn from Ldlr2/2
(n = 4; left panels) and WT mice (n = 4; right panels) 5 days after injection with 2.109 pfu of Ad.Znf202 (filled bars) or with Ad-mock (open bars) and
derived plasma was analyzed for triglyceride and total cholesterol content (A). Lipoprotein profiles were determined from Ldlr2/2 (left panels) and
WT mice (right panels) 5 days after injection with Ad.Znf202 (triangles) or with Ad-Mock (squares). The elution fractions were tested for triglyceride
and total cholesterol content (B). * and ** indicates p,0.05 and p,0.001, respectively.
doi:10.1371/journal.pone.0057492.g003
Figure 4. Hepatic Znf202 overexpression causes hepatosteatosis in Ldlr2/2 mice only. Livers were isolated from Ldlr2/2 and WT mice 5
days after injection with 2.109 pfu of Ad.Znf202 (filled bars) or Ad-mock (empty bars). Cryosections were prepared from Ldlr2/2 liver samples and
stained with Oil Red-O (A). Hepatic lipids were extracted from homogenized liver samples and cholesterol and TG concentrations were determined
(B). Values are expressed as mg lipid per mg tissue protein and are means 6 SD (n = 4). * indicates p,0.05.
doi:10.1371/journal.pone.0057492.g004
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homogenized and protein content was determined by a Lowry
assay using BSA as calibration standard. Lipids were extracted
from the homogenate according to Bligh and Dyer. After
evaporation, lipids were dissolved in a 2% Triton-X-100 solution
and cholesterol and triglyceride levels were determined as
described above.
Data Analysis
All results are presented as means 6 SD. The significance of
differences in relative gene expression was calculated using a two-
tailed Student’s t test. Differences in lipid, lipoprotein and enzyme
activity levels were analyzed statistically by Mann-Whitney-U test.
Probability values less than 0.05 were considered significant.
Results
Znf202 Repressed the Expression of Apolipoprotein
Genes in vitro
The functionality of the generated recombinant plasmids and
adenovirus carrying containing the Znf202 gene construct was
verified in vitro. As readout, we analyzed the effect of Znf202
overexpression on the Apoe/c1/c2 and Apoa1/c3/a4/a5 gene
clusters in mhAT3F2 cells. Cyclophylin or 36B4 expression by
transduced mhAT3F2 cells was not affected by Ad.Znf202
transduction (Fig.1A). However, Znf202 overexpression did result
in a significant downregulation of apolipoprotein genes from both
clusters. RNA levels were reduced up to 50% (ApoC2 and ApoC3)
and reached significance for all genes (p,0.05) except Apoa5.
The repressive effect of Znf202 on the expression of one
member of investigated apolipoprotein gene clusters, Apoe, has
already been demonstrated and was therefore used to address the
regulatory capacity of Znf202 [12,18] and to identify its
interaction with the mouse ApoE promoter sequence in a reporter
assay. The presence of nucleotide sequences spanning 2362 to
290 was seen to enhance promoter activity in mhAT3F2 cells as
expected [25,26], while the addition of region 2705/2362
attenuated the enhanced activity to up to 4-fold (Fig.1B). To
investigate the repressive effect of Znf202 on the ApoE promoter
activity, we co-transfected various promoter-reporter constructs
and Znf202 expression vector. Znf202 appeared to repress
transcriptional activity of the ApoE promoter only when the
complete 2705/+24 region was present (Fig.1C). Deletion of the
59 end (2705/2362) abolished the repressive effect of Znf202 on
the ApoE promoter activity.
With the Znf202 repressive effect on ApoE promoter activity
restricted to the 2705/2362 region, we studied the interaction of
Znf202 with the two putative GnT sites within this domain at
positions 2678 and 2564 (Fig. 2A) by EMSA. The GnT control
probe (Fig. 2B, lanes 1–10) induced a clear mobility shift indicative
of the formation of DNA-protein complexes in extracts from
Znf202 overexpressing 911 cells (lanes 3, 6, 9). Probe binding was
specifically competed by 50-fold excess of unlabeled GnT probe
(lane 4, 7, 10). Similar mobility shifts were observed for the [32P]-
678 (lanes 11–20) or [32P] 2564 probe (lanes 21–30) after Znf202
overexpression. In analogy to the reference probe, the specificity of
binding was confirmed by displacement by a 50-fold excess of
either unlabeled 2678 or 2564 probe. Finally, the extracts were
unable to form DNA-protein complexes with an irrelevant PHO
consensus probe, even at high concentrations (lanes 32 and 33).
These in vitro results confirm the repressive role of Znf202 and
establish the functionality of our murine Znf202 constructs.
HDL Cholesterol Levels Markedly Reduced after Five Days
of Hepatic Znf202 Overexpression
To address the role of Znf202 in lipid metabolism in vivo, we
have overexpressed Znf202 in two mouse strains: normolipidemic
C57Bl/6J (WT) and hyperlipidemic Ldlr2/2 by adenoviral gene
transfer. Relative baseline expression of endogenous hepatic
Znf202 showed no difference between both mouse models (data
not shown). The expression level of Znf202 is relatively low (CT ,
30). Thus, the injection of Ad.Znf202 in Ldlr2/2 and WT mice
resulted in a substantial hepatic overexpression of the transgene
after 5 days from DCT=24 (Ad.mock) to DCT=4 and 5,
respectively (Fig. S1; relative expression compared to control
genes, using real-time PCR analysis; P,0.001). Absolute expres-
sion levels of the housekeeping genes remained unaltered after
Ad.Znf202 treatment.
Plasma total cholesterol (TC) levels were 2-fold increased in
Ad.Znf202 treated Ldlr2/2 mice on day 5 after gene transfer
(P,0.001), whereas in WT mice Znf202 overexpression had a
slight lowering effect on plasma TC levels (Fig. 3A). Surprisingly,
triglyceride (TG) levels were reduced by 4-fold (P,0.05) in Ldlr2/
2 mice only. The elevated plasma TC levels in Ldlr2/2 mice
overexpressing Znf202 appeared to be attributable to an increased
cholesterol content of the VLDL pool (Fig. 3B). In keeping with its
presumed role in hypoalphalipoproteinemia, Znf202 overexpres-
sion led to a marked reduction in HDL-cholesterol both in WT
and in Ldlr2/2 mice (263% and 270% respectively).
Hepatic Znf202 Overexpression Induces Hepatosteatosis
in Ldlr2/2
Histological analysis of livers isolated from Ad.Znf202 and
Ad.Mock treated Ldlr2/2 and WT mice at day 5 post
transduction revealed some striking differences. In Ldlr2/2 mice,
Znf202 overexpressing livers were characterized by massive oil-
red-O stained lipid deposition in intracellular vacuoles mainly
(Fig. 4A), while liver morphology of Znf202 transduced WT mice
Table 1. Relative gene expression in livers 5 days after
infection with Ad-mock or Ad-Znf202 in Ldlr2/2 and wild
type mice.
Ldlr2/2 Wild Type
Ad-mock Ad-Znf202 Ad-mock Ad-Znf202
ApoE 1.0060.47 0.9760.40 1.0060.23 1.1060.18
ApoC1 1.0060.28 0.7860.39 1.0060.43 1.1560.10
ApoC2 1.0060.65 3.2760.36* 1.0060.28 1.6160.21*
ApoA1 1.0060.62 0.6560.33 1.0060.27 0.8360.20
ApoC3 1.0060.54 0.9360.25 1.0060.35 0.9060.15
ApoA4 1.0060.57 0.8160.30 1.0060.50 0.3760.19*
ApoA5 1.0060.35 2.8760.31* 1.0060.11 1.5360.29*
Abca1 1.0060.31 1.2560.21 1.0060.24 1.0860.22
Abcg5 1.0061.06 0.7160.67 1.0060.47 0.8060.37
Abcg8 1.0060.59 0.8360.40 1.0060.50 0.9960.21
Ldlr – – 1.0060.28 0,8860,22
Sr-b1 1.0060.98 0.5160.39 1.0060.27 0.9160.29
Hmg-CoA red. 1.0060.92 0.5860.13 1.0060.31 0.9360.13
Cyp7a1 1.0060.51 1.0960.73 1.0060.72 3.0060.24*
Values are expressed as means 6 SD.
*Indicates a significant difference (p,0.05) between Ad.Znf202 treated animals
and their corresponding Ad.mock treated controls.
doi:10.1371/journal.pone.0057492.t001
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was normal (data not shown). As liver morphology of Ad.Znf202
treated mice was highly reminiscent of steatosis, we assayed the
liver lipid content quantitatively. As can be appreciated from
figure 4B, Znf202 overexpressing livers from Ldlr2/2 mice
contained over 2-fold higher TC, cholesteryl esters (CE), and
TG. In line with their normal liver morphology, no changes in
hepatic lipid content were observed in Znf202 transduced WT
mice.
Gene Expression Profile After Adenovirus Mediated Gene
Transfer of Znf202
Since Znf202 has been reported to be a potent transcriptional
repressor of various key genes in lipoprotein metabolism [12], we
mapped the hepatic expression profile of a range of putative
Znf202 responsive genes at day 5 after Ad.Znf202 or Ad.mock
treatment of Ldlr2/2 and WT mice. Unexpectedly, analysis of
the Apoe/c1/c2 and Apoa1/c3/a4/a5 gene clusters showed that
Figure 5. Znf202 overexression results in the reduced lipid related gene expression and affects plasma lipid levels in vivo. mRNA
levels relative to control genes in livers from Ldlr- 24 hrs after injection with Ad.Znf202 (filled bars) or Ad.mock (empty bars) (A). Plasma samples were
taken before (day 0) and 1 day after injection with Ad.Znf202-treated (filled bars) and Ad.mock-treated animals (open bars) to determine the total
plasma cholesterol and triglycerides content. Plasma samples obtained from day 1 after injection with Ad.Znf202 (triangles) or with Ad.mock
(squares) were also analyzed for lipoprotein profile (B). Data are means 6 S.D (n = 5). * and ** indicates p,0.05 and p,0.001 respectively.
doi:10.1371/journal.pone.0057492.g005
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Znf202 overexpression even increased the expression of Apoc2 and
Apoa5 in WT (1,5-fold) and Ldlr2/2 mice (3-fold) (both P,0.05)
(table 1). In contrast, Znf202 overexpression did not change Apoe,
Apoa1, Apoc1, and Apoc3 expression, even though these genes were
seen to be Znf202 responsive in previous in vitro studies [5,11].
Only Apoa4 expression was found to be significantly reduced upon
Znf202 overexpression in WT mice.
In search of a possible explanation for the elevated intrahepatic
cholesterol levels, we determined gene expression levels of
cholesterol related genes. Znf202 overexpression did not alter
gene expression of major cholesterol transporters Abca1, Abcg5,
Abcg8, Sr-b1, and Ldlr (in WT). The gene expressions of Abcg1 and
LDL receptor related protein (Lrp) were unaffected as well (table
S3). With regard to cholesterol synthesis, no change in the
expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-
CoA reductase) was observed. Interestingly, the bile acid synthesis
gene cholesterol 7a-hydroxylase (Cyp7A1) was differentially affect-
ed between WT and Ldlr2/2 mice upon Znf202 expression. In
Ldlr2/2 it was unchanged while it was increased in WT (.3-
fold). The increased cyp7A1 expression was confirmed at a protein
level, as liver extracts from Ad.Znf202 treated WT but not Ldlr2/
2 mice showed sharply enhanced cyp7A1 activity (Fig. S2).
Lipid homeostasis is under tight control of nuclear receptors
[27]. Next, we investigated whether Znf202 could have influenced
apolipoprotein and lipid flux gene expression in an indirect
manner by modulating nuclear receptor dependent regulatory
pathways. The transcription factors Hnf-4, Ppara, Ppard, LXRa/b
and FXR were downregulated in Ldlr2/2 mice by 25 to 60%
(P,0.05) (table S3), while surprisingly no effect was found in WT
mice.
As a measure of inflammatory responses potentially inflicted by
adenoviral gene transfer we assessed hepatic MARCO and CD68
mRNA levels. The expression of both genes remained essentially
unaltered by Znf202 treatment (1.060.8 and 1.06.0.6 for Ad-
mock versus 0.760.4 and 1.260.2 for Ad.Znf202 treated Ldlr2/
2 mice), thus confirming the histological finding that Znf202 did
not promote massive leukocyte recruitment to the liver and
excluding that adenovirus elicited inflammatory responses are
underlying the observed phenotype in Ldlr2/2 mice.
Bile Flux Genes Repressed After 24 hrs of Hepatic Znf202
Overexpression in vivo
Despite hypoalphalipoproteinemia and the dramatic changes in
lipid levels, especially in Ldlr2/2, we did not observe any of the
expected, repressive effects of Znf202 on hepatic expression of
target genes in vivo at 5 day post-transduction. In addition, several
lipid related nuclear receptors were dysregulated in Znf202
overexpressing Ldlr2/2 mice, although none had been reported
to be Znf202 responsive. Conceivably, the initial and suppressive
effects of Znf202 overexpression are overruled by secondary
effects, which may underly the severe phenotype observed in
Ldlr2/2 mice. To address this notion, we have monitored hepatic
gene expression patterns and lipid homeostasis in the mouse model
that was mostly affected, the Ldlr2/2, at 24 hours after
transduction. In line with the in vitro results, this increase in
hepatic Znf202 gene expression (Fig. S1; from DCT=214 to
DCT=211) resulted in the reduced expression of several genes
within both apolipoprotein gene clusters in the liver (Fig 5A). The
mRNA levels of Apoa1, Apoc1, Apoc1, and Apoe were approximately
2-fold reduced. Interestingly, we also observed a lowered
expression (.70%) of the sterol transporter genes Abcg5 and Abcg8
and the bile salt efflux protein (Bsep). Most notably, the expression
of the bile acid synthesis gene cholesterol 7a-hydroxylase (Cyp7a1)
was more that 1000 fold reduced upon treatment with Ad.Znf202
(P,0.001). The attenuated expression of these bile flux genes
suggests that hepatic overexpression of Znf202 affects the biliary
secretion. The expression of several lipid related transcription
factors such as Fxr, Ppara, and Srepb1 was also reduced by hepatic
Znf202 overexpression (table S4). However, a well described target
gene of Znf202, Abca1, was unaffected. Additionally, the expres-
sion of HMG-CoA reductase, an important enzyme in cholesterol
synthesis, was increased.
Figure 6. Proposed mechanism for Znf202. Elevated hepatic levels of Znf202 downregulate bile flux genes. Together with an increase in
cholesterol synthesis and attenuated bile acid synthesis, this could result in the observed lipid accumulation in the liver and increased VLDL secretion
(A). Under normolipidemic conditions, feedback mechanisms are able to reverse most of the initial effects of Znf202 overexpression (B). These initial
effects cannot be sufficiently restored in mice under the hyperlipidemic conditions caused by the low density lipoprotein receptor deficiency. As a
result, the mice become more hyperlipidemic and the lipid accumulation in the liver is followed by hepatic steatosis (C).
doi:10.1371/journal.pone.0057492.g006
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Together with the altered hepatic gene expression pattern,
hepatic Znf202 overexpression had an effect on lipid metabolism
already at 24 h post infection. Total cholesterol and triglycerides
(TG) levels were markedly elevated (Fig. 5B). These changes in
plasma lipids could mainly be ascribed to increased very low
density lipoprotein (VLDL). The accumulation of intrahepatic
lipids as manifested after 5 days of hepatic Znf202 overexpression,
could not be detected at this early time point (data not shown).
Discussion
Based on genetic and in vitro studies, the transcriptional
repressor Znf202 has been proposed as a key regulator of lipid
homeostasis and in particular of lipid efflux [28]. However, while
its repressor function in vitro is well established, the precise role of
Znf202 in lipid metabolism in vivo remains to be addressed.
Despite these initial studies that link Znf202 to HDL, Stene and
colleagues were unable to demonstrate a direct correlation
between genetic variation within the znf202 gene and HDL
cholesterol levels [13]. However, at least one genetic variant was
seen to be predictive of a high risk for cardiovascular diseases [29].
In this study we are the first to show, through a gain of function
approach involving adenoviral Znf202 gene transfer, a role of
Znf202 in lipid metabolism in mice.
To confirm the repressive effect of our Znf202 constructs, we
overexpressed murine Znf202 in a mouse hepatoma cell line and
showed reduction of expression of the majority of genes within
both apolipoprotein gene clusters. The repressive nature of this
transcription factor was further established in studies with the
murine ApoE promoter. Screening of the proximal region of the
murine Apoe gene for potential Znf202 binding sites revealed five
GnT consensus sites (positions 2678, 2564, 2338, 2315, 2160),
of which the first two were shown to carry functional suppressor
elements. Removal of these sites ablated Znf202 responsiveness. In
addition, Znf202 was seen to specifically interact with the GnT
sites within the responsive 2705/2362 region, confirming the
specific DNA binding characteristics of Znf202. Because the intron
regulatory element 1 (IRE1), situated between exon 1 and exon 2
of the Apoe gene, also contains regulatory elements, we tested the
effect of IRE1 [25]. Even though its mere presence reduced
promoter activity 2-fold, the overall pattern of expressional
regulation by Znf202 was not affected (data not shown).
To investigate the role of Znf202 in vivo, the effect of hepatic
znf202 overexpression on lipid homeostasis was assessed in hyper-
and normolipidemic mice 5 days after adenoviral Znf202 gene
transfer. In keeping with earlier genetic and in vitro studies
hepatic Znf202 overexpression was accompanied by hypoalpha-
lipoproteinemia both under normolipidemic (WT mice) and
hyperlipidemic conditions (Ldlr2/2 mice). Furthermore, it was
seen to cause hypercholesterolemia and hypotriglyceridemia with
concommittant steatosis in Ldlr2/2 but not WT mice. Hepatic
lipid accumulation was not accompanied by hepatic inflammation
excluding that our findings reflect an inflammatory response to
adenoviral infection. However, except for apoa4 in WT, we did not
observe overt repression of members of the Apoe/c1/c2 and Apoa1/
c3/a4/a5 gene clusters in liver of both normo- and hyperlipidemic
mice. Also the expression of other lipid related genes including the
znf202 target genes Abca1 and Abcg1 [30] was not affected by
hepatic Znf202 overexpression.
Although these in vivo data clearly link znf202 activity to
hypoalphalipoproteinemia, the apparent lack of correlation
between the in vitro data of us and others and the hepatic gene
expression profiles at 5 days after adenoviral Znf202 administra-
tion was a surprise. This discrepancy might be caused by changes
in lipid driven transcriptional factors like Ppar, Lxr, and Fxr in
response to Znf202 induced dyslipidemia. For this reason, we
analyzed the immediate response in the mouse model that was
most affected, the Ldlr2/2. After only 24 hours of hepatic Znf202
overexpression, we did observe lowered expression of members of
both apolipoprotein gene clusters. Interestingly, several key genes
involved in bile flux and most notably Cyp7a1 were profoundly
repressed by Znf202 as well. Closer analysis of the promoter
sequence of murine Cyp7a1, expression revealed a putative Znf202
binding (GnT) site at position2862 bp. Surprisingly, this effect on
Cyp7A1 expression coincided with an increase in Hmg-CoA
reductase expression suggestive of augmented de novo hepatic
cholesterol synthesis. A similar compensatory response to de-
creased hepatic cholesterol input was seen in studies on the
inhibition of sterol absorption by ezetimibe [31,32]. Conceivably,
one of the initial responses to Znf202 overexpression may involve
the reduced hepatic cholesterol uptake. Nonetheless, the suppres-
sive effect of Znf202 overexpression on bile flux genes such as
cyp7A1 and the concomitant Hmg-CoA reductase upregulation, may
explain the strong hepatic lipid accumulation in Ldlr2/2 as
apparent at day 5 post infection [33,34].
Znf202 overexpression led to changed expression of the
transcriptional regulators of lipid metabolism Fxr, Srepb1, and
Ppara. FXR, a negative regulator of Cyp7a1 expression, was down-
and not upregulated. Upregulation of Srebp1 and Ppara has been
associated with lipogenesis and hepatic accumulation of lipids,
respectively [35]. It remains to be determined whether and how
the observed reduced expressions can contribute to the hepatos-
teatosis in Znf202-treated Ldlr2/2.
In response to hepatic Znf202 overexpression in hyperlipidemic
Ldlr2/2 mice, both VLDL-cholesterol and VLDL-triglycerides
were increased within 24 hours. Although potentially reflecting a
direct effect of Znf202, the increased VLDL secretion could well
be the result of increased hepatic lipids as described previously
[36,37]. While the increase in VLDL-cholesterol persisted for at
least 4 days, triglyceride levels were sharply reduced in the same
time span. Our gene expression analysis revealed increased
expression of Apoa5 and Apoc2 at 5 days of Znf202 overexpression
both in Ldlr2/2 and WT mice. Both ApoA5 and ApoC2 have
been implicated in TG metabolism and in particular TG
hydrolysis. Studies by Schaap et al. [38], and by Pennacchio
et al. [39], already demonstrated a clear inverse relationship
between serum ApoA5 and VLDL-TG levels. Similarly, ApoC2
functions as cofactor in LPL-mediated TG hydrolysis [40] and
ApoC2 deficiency in humans is associated with severe hypertri-
glyceridemia [41]. In line with these findings, chronic Znf202
overexpression in Ldlr2/2 mice indeed sharply reduced serum
triglyceride levels compared to Ad-mock treated controls.
Whereas lipid homeostasis in hyperlipidemic LDLr2/2 mice
was strongly affected by Znf202 overexpression, normolipidemic
mice only showed mild effects. The moderate effect on total serum
lipid levels in WT mice could be attributed in part to clearance via
the LDLR. Moreover, additional secondary effects due to a
progressively increased VLDL-TG lipolysis and panlobular lipid
accumulation are not opportune in WT mice. In contrast to
Ldlr2/2, the livers of WT mice show no accumulation of lipids
upon Znf202 overexpression at day 5. Interestingly, while in
Ldlr2/2 the gene expression of cyp7a1, a key enzyme in bile acid
synthesis [42], was apparently normalized after an initial strong
Znf202 induced downregulation, it was strongly upregulated in
normolipidemic mice. The latter response may underly the mild
phenotype seen in WT mice which leads us to propose that the
in vivo impact of Znf202 expression depends on the hyperlipid-
emic status (Fig. 6). Znf202 overexpression directly modulates bile
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flux gene expression resulting in hepatic lipid accumulation and a
subsequent increase in VLDL secretion. Whereas initial effects on
many of the established znf202 responsive hepatic genes appear to
be compensated by a yet unknown mechanism, Znf202 overex-
pression did result in reduced HDL-cholesterol levels both in
normo- and in hyperlipidemic mice. Whether or not Znf202 is the
responsible gene within the identified chromosomal region that
has been linked to hypoalphalipoproteinemia in the study with
Utah pedigrees [11] and has a direct or indirect association with
the increased risk of coronary heart disease requires further
investigation.
The relative levels of Znf202 mRNA in the livers were
substantially high upon injection with Ad.Znf202, especially after
5 days (Fig. S1). Part of the explanation is probably the low
endogenous hepatic expression of this regulatory factor measured
in both mouse models before treatment. Therefore, the achieved
relative mRNA levels after the gene transfer appear very high
compared to the control group. Nonetheless, our finding
corroborates previous reports that Znf202 is linked to HDL
metabolism [11,28]. Yet, how exactly Znf202 affects circulating
HDL remains unclear. The initial reduction in expression of
ApoA1, a major component of HDL, could partly explain the
lower HDL levels observed at later time points after znf202
overexpression. In part, it might be associated with the induced
apoA5 expression in both WT and Ldlr2/2 mice. Previous
studies have shown a significant and dose-dependent decrease in
serum HDL levels after Apoa5 overexpression in WT mice [43]. Of
note, the expression of two other putative Znf202 targets that
potentially can influence HDL levels, i.e. lipoprotein lipase and
lecithin: cholesteryl acetyl transferase, were not affected in the liver
[12,44,45] (tables S3 and S4).
In conclusion, we are the first to deliver in vivo proof for a
functional role of Znf202 in lipid homeostasis and that znf202
overexpression causes hypoalphalipoproteinemia both in normo-
lipidemic and hyperlipidemic mouse models. In mice lacking Ldlr,
Znf202 overexpression also was seen to induce severe hepatic lipid
accumulation and dyslipidemia. These mice develop pronounced
steatosis within 5 days, after initial downregulation of the
expression of key genes in cholesterol and bile salt transport and
bile acid formation. The in vivo results obtained with Ldlr2/2
suggest that genetic defects in Znf202 might have even more
impact in hyperlipidemic subjects. This study thus establishes
in vivo a key role of Znf202 in HDL metabolism and in
maintaining lipid homeostasis.
Supporting Information
Figure S1 Increased hepatic Znf202 mRNA levels after
injection with Ad.Znf202 compared to Ad.mock. Znf202
mRNA levels relative to control genes in livers were determined
24 hrs (Ldlr2/2 mice; n= 5) and 5 days (WT and Ldlr2/2 mice;
n = 4) after injection with Ad.Znf202 (filled bars) or Ad-mock
(empty bars). Data are means 6 S.D.
(TIF)
Figure S2 Liver analysis for Cyp7A1 activity revealed a
significant Cyp7A1 induction in WT mice but not in
Ldlr2/2 mice at 5 days post-infection. Liver was excised
from Ldlr2/2 and WT mice 5 days after injection with 2.109 pfu
of Ad.Znf202 (filled bars) or Ad-mock (empty bars) and cyp7A1
activity was measured. Data are means 6 S.D. of N=4
determinations and ** indicates p,0.001.
(TIF)
Table S1 Primers used to generate the apoE promotor
constructs.
(TIF)
Table S2 Primers sets used for quantitative real-time
PCR.
(TIF)
Table S3 Relative gene expression in livers 5 days after
infection with Ad-mock or Ad-Znf202 in Ldlr2/2 and
wild type mice. Values are expressed as means 6 SD.
(DOC)
Table S4 Relative gene expression in livers 24 hours
after infection with Ad-mock or Ad-Znf202 in Ldlr2/2.
Values are expressed as means 6 SD.
(DOC)
Text S1 Supplementary material and methods.
(DOC)
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